N-[4-氯-3-(三异丙基硅烷基氧基)苯基]-2,2-二甲基丙酰胺 | 342621-20-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-[4-氯-3-(三异丙基硅烷基氧基)苯基]-2,2-二甲基丙酰胺
• 英文名称: N-[4-Chloro-3-(triisopropylsilyloxy)phenyl]-2,2-dimethylpropanamide
• 英文别名: N-[4-chloro-3-tri(propan-2-yl)silyloxyphenyl]-2,2-dimethylpropanamide
• CAS: 342621-20-9
• 化学式: C₂₀H₃₄ClNO₂Si
• 分子量: 384.034
• InChiKey: YKMTWGAOPDJDTR-UHFFFAOYSA-N

物化性质

• 沸点：
  458.6±35.0 °C(Predicted)
• 密度：
  1.018±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于二氯甲烷、乙酸乙酯

计算性质

• 辛醇/水分配系数(LogP)：
  6.88
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[4-氯-3-(三异丙基硅烷基氧基)苯基]-2,2-二甲基丙酰胺 在 盐酸 、 仲丁基锂 作用下， 以 乙二醇二甲醚 、 乙醚 为溶剂， 生成 2-三氟乙酰基-4-氯-5-羟基苯胺
  参考文献：
  名称：

  Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor Efavirenz

  摘要：

  Studies on the biotransformation of the clinically important non-nucleoside reverse transcriptase inhibitor efavirenz have shown that oxidation and secondary conjugation are important components of the processing of this molecule in vivo. We have synthesized metabolites of efavirenz to confirm their structure and to evaluate their activity as antivirals. (C) 2001 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00012-9
• 作为产物：
  描述：

  2-氯-5-硝基苯酚 在 palladium on activated charcoal 咪唑 、 氢气 、 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[4-氯-3-(三异丙基硅烷基氧基)苯基]-2,2-二甲基丙酰胺
  参考文献：
  名称：

  Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor Efavirenz

  摘要：

  Studies on the biotransformation of the clinically important non-nucleoside reverse transcriptase inhibitor efavirenz have shown that oxidation and secondary conjugation are important components of the processing of this molecule in vivo. We have synthesized metabolites of efavirenz to confirm their structure and to evaluate their activity as antivirals. (C) 2001 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00012-9

文献信息

• Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor Efavirenz
  作者：Jay A. Markwalder、David D. Christ、Abdul Mutlib、Beverly C. Cordova、Ronald M. Klabe、Steven P. Seitz

  DOI：10.1016/s0960-894x(01)00012-9

  日期：2001.3

  Studies on the biotransformation of the clinically important non-nucleoside reverse transcriptase inhibitor efavirenz have shown that oxidation and secondary conjugation are important components of the processing of this molecule in vivo. We have synthesized metabolites of efavirenz to confirm their structure and to evaluate their activity as antivirals. (C) 2001 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.